Ipsen S.A. (OTCMKTS:IPSEY) Short Interest Down 38.1% in September

Ipsen S.A. (OTCMKTS:IPSEY) was the target of a large drop in short interest during the month of September. As of September 30th, there was short interest totalling 1,300 shares, a drop of 38.1% from the September 15th total of 2,100 shares. Based on an average trading volume of 2,300 shares, the days-to-cover ratio is presently 0.6 days.

Wall Street Analyst Weigh In

Separately, Royal Bank of Canada upgraded shares of Ipsen from a “hold” rating to a “moderate buy” rating in a report on Monday, September 16th.

Ipsen Trading Up 0.9 %

IPSEY stock opened at $31.13 on Monday. Ipsen has a 1-year low of $26.97 and a 1-year high of $34.06. The business’s 50-day moving average price is $29.96 and its two-hundred day moving average price is $30.49.

Ipsen Company Profile

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.